Biocon shares increased by 4.5% after the US FDA classified its Malaysian insulin facilities as Voluntary Action Indicated.

Shares of Biocon were in high demand on Monday after the pharmaceutical company's subsidiary Biocon Biologics' Johor Bahru ...

Clearance of Biocon's Malaysia unit puts an end to the drugmaker's regulatory hurdles and opens the door for the approval and ...

With an increased confidence in the company’s prospects, HSBC raised its earnings estimates for Biocon, projecting ...

Brokerages have turned bullish over Biocon's growth prospects after the US FDA clearance of the drugmaker's Malaysia unit ...

Biocon’s shares surged over 7% on January 14, 2025, after HSBC upgraded its rating to ’Buy’ with a target price of ₹430, ...

According to reports, HSBC said that Biocon is well-placed for an operational turnaround, driven by key biosimilar launches ...

After the clearance from US drugs regulator, Motilal Oswal has upgraded Biocon to 'buy' with a target price of Rs 430 apiece.

Analysts said that assuming a $700 million market size for gAspart, Biocon can see US sales worth $25 million and $50 million ...

for the insulin facility of Biocon Biologics in Malaysia. This development marks the resolution of a significant regulatory ...

HSBC expects an operational turnaround for Biocon, driven by major biosimilar launches and a rebound in generics sales. The ...

Shares of Biocon surged as much as 5 per cent during the trading session on Monday after the USFDA cleared Malaysia unit to end regulatory hurdles for the pharma player.